Zorotab DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the effective management of gastrointestinal disorders. Domperidone, a dopamine D2 receptor antagonist, enhances gastrointestinal motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and discomfort associated with delayed gastric emptying and gastroparesis. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing relief from acid-related conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. The synergistic action of these two agents in Zorotab DSR Capsule offers both symptomatic relief and mucosal healing by addressing both motility and acid secretion abnormalities. It is indicated for conditions where delayed gastric emptying coexists with acid-related disorders. Zorotab DSR should be used under medical supervision, with caution advised in patients with known hypersensitivity to either component, underlying cardiac conditions, or hepatic impairment. Common adverse effects may include headache, dry mouth, or gastrointestinal disturbances. This combination therapy optimizes patient compliance by reducing pill burden and enhancing therapeutic efficacy in the management of complex upper gastrointestinal disorders.